Outcomes of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor use in neutropenic patients infected with human immunodeficiency virus

International Journal of Infectious Diseases

Volumn 3, Issue 2, 1999, Pages 70-75

  Ambati, Balamurali K ^a   Perlman, David C ^a   Salomon, Nadim ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Granulocyte colony stimulating factor; Granulocyte macrophage colony stimulating factor; HIV; Neutropenia

Indexed keywords

CD4 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANALYSIS OF VARIANCE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032408222     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1201-9712(99)90012-7     Document Type: Article

References (25)

1. Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 1987; 66:337-340.
2. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever: a statement by the Infectious Diseases Society of America. J Infect Dis 1991; 162:381-396.
3. Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 1993; 7:771-793.
4. Farber BF, Lesser M, Kaplan MH, et al. Clinical significance of neutropenia in patients with human immunodeficiency virus infection. Infect Control Hosp Epidemiol 1991; 12: 429-434.
5. Whimbey E, Gold JWM, Polsky B, et al. Bacteremia and fungemia in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104:511-514.
6. Hambleton J, Aragon T, Modin G, et al. Outcome for hospitalized patients with fever and neutropenia who are infected with the human immunodeficiency virus. Clin Infect Dis 1995; 20:363-371.
7. Moore RD, Keruly JC, Chaisson RE. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 1995; 155:1965-1970.
8. Shaunak S, Bartlett JA. Zidovudine-induced neutropenia: Are we too cautious? Lancet 1989; 2:91-92.
9. Tumbarello M, Tacconelli E, Caponera S, et al. Impact of bacteremia on HIV infection: nine years' experience in a large Italian university hospital. J Infect 1995; 31:123-131.
10. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992; 327:99-106.
11. Hartmann LC, Tschetter LK, Habermann TM, et al. G-CSF in severe chemotherapy induced afebrile neutropenia. N Engl J Med 1997; 336:1776-1780.
12. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:492-501.
13. Anaissie E, Vartivarian S, Bodey GP, et al. Randomized comparison between antibiotics alone and antibiotics plus GM-CSF (Escherichia coll-derived) in cancer patients with fever and neutropenia. Am J Med 1996; 100:17-23.
14. Dombret H, Chastang C, Fenaus P, et al. A controlled study of recombinant human-granulocyte colony-stimulating fac-tor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995; 332:1678-1683.
15. Ottmann OG, Hoelzer D, Gracien E, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995; 86:444-450.
16. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994; 12: 2471-2508.
17. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14:1957-1960.
18. Hermans P. Clinical use of haematological growth factors in patients with human immunodeficiency virus (HIV-1) infection. Biomed Pharmacother 1994; 48:69-72.
19. Miles SA. The use of haematopoietic growth factors in HIV infection and AIDS-related malignancies. Cancer Invest 1991; 9:229-238.
20. Kimura S, Matsuda J, Ikematsu S, et al. Efficacy of recombinant G-CSF on neutropenia in patients with AIDS. AIDS 1990; 4:1251-1255.
21. Kuritzkes D, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. AIDS 1998; 12:65-74.
22. Keiser P, Rademacher S, Smith J, et al. G-CSF use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients. Am J Med 1998; 104:48-55.
23. De Pauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994; 120:834-944.
24. Report of the Task Force of Microbiology and Infectious Diseases. NIH Publication No. 92-3220. Bethesda, MD: National Institute of Allergy and Infectious Diseases, April 1992.
25. Meynard JL, Guiguet M, Arsac S, et al. Frequency and risk factors of infectious complications in neutropenic patients infected with HIV. AIDS 1997; 11:995-998.